Trial · NCT01577654
Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
NCT01577654, Phase 2, Completed, Endocyte
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer. Trials, record NCT01577654. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01577654
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
- NCT number
- NCT01577654
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 203 participants, actual
- Lead sponsor
- Endocyte
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- EC145, EC145 + Docetaxel, Docetaxel, EC20
- First posted
- 2012-04-16
- Last updated
- 2021-04-01
- Other registries' IDs
- eudract:2012-000966-40
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival(PFS)based on investigator assessment using RECIST v1.1 | From date of baseline disease assessment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 26 months | Disease assessment will be conducted via CT/ MRI every 6 weeks while on study. Participants who come off study due to any other reason except progression of disease or death will be followed via CT/ MRI every 6 weeks until disease progression or until start of new therapy. |
| Secondary | Compare overall response rate of participants between treatment arms. | up to 26 months | Analysis will occur when approximately 50% of the PFS events have occurred (for each comparison) and when 94 PFS events have occurred. |
| Secondary | Compare disease control rate of participants between treatment arms. | up to 26 months | Analysis will occur when approximately 50% of the PFS events have occurred (for each comparison) and when 94 PFS events have occurred. |
| Secondary | Compare duration of response of participants between treatment arms. | up to 26 months | Analysis will occur when approximately 50% of the PFS events gave occurred (for each comparison) and when 94 PFS events have occurred. |
| Secondary | Compare duration of disease control of participants between treatment arms. | up to 26 months | Analysis will occur when approximately 50% of the PFS events gave occurred (for each comparison) and when 94 PFS events have occurred. |
| Secondary | Compare overall survival of participants between treatment arms. | up to 26 months | Analysis will occur when approximately 50% of the PFS events gave occurred (for each comparison) and when 94 PFS events have occurred. |
| Secondary | Incidence of Adverse Events, Serious Adverse Events, and Deaths. | up to 26 months | Adverse events (as a measure of safety and tolerability) will be assessed at each study visit. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01577654
GET https://conductscience.org/api/trials/v1/NCT01577654/registered